CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Last trade$1.56
Day change-$0.11 (-6.59%)
Day range$1.55 – $1.75
Volume240,350
Market cap$25M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$25.26M
Price / earnings
—
Price / book
1.46×
Price / sales
2,895.33×
EV / sales
2,200.88×
EV / EBITDA
-0.66×
Profitability
Earnings per share
-$1.89
Return on assets
-133.7%
Return on equity
-164.32%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.37×
Quick ratio
5.37×
Cash ratio
1.52×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$26.59M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRVO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$8.73K
$322.57K
$1.76M
$1.92M
$2.16M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$8.73K
$322.57K
$1.76M
$1.92M
$2.16M
Selling, general and administrative
$2.43M
$2.36M
$2.98M
$2.51M
$2.33M
$3.27M
$2.38M
$2.32M
Research and development
$3.68M
$4.32M
$5.14M
$5.83M
$6.04M
$5.11M
$4.84M
$7.09M
Total operating expenses
$6.1M
$6.68M
$8.11M
$8.34M
$8.37M
$8.37M
$7.22M
$9.4M
Operating income
-$6.1M
-$6.68M
-$8.11M
-$8.33M
-$8.04M
-$6.62M
-$5.3M
-$7.24M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$5.9M
-$6.57M
-$7.96M
-$8.09M
-$7.73M
-$6.26M
-$4.89M
-$6.71M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.9M
-$6.57M
-$7.96M
-$8.09M
-$7.73M
-$6.26M
-$4.89M
-$6.71M
Net income attributable to common shareholders
-$5.9M
-$6.57M
-$7.96M
-$8.09M
-$7.73M
-$6.26M
-$4.89M
-$6.71M
EBITDA
-$6.1M
-$6.68M
-$8.11M
-$8.33M
-$8.04M
-$6.62M
-$5.3M
-$7.24M
Basic earnings per share
-$0.39
-$0.64
-$0.86
-$0.87
-$0.84
-$0.70
-$0.56
-$0.77
Diluted earnings per share
-$0.39
-$0.64
-$0.86
-$0.87
-$0.84
-$0.70
-$0.56
-$0.77
Recent news
Company coverage with links to the original publishers.
Agenus (AGEN) reported Q3 2026 earnings of $0.02 per share, matching consensus estimates but missing revenue expectations by 10.03% at $31.49 million. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions, suggesting underperformance ahead. Despite a 122% year-to-date gain, the biotech company has only surpassed EPS estimates once in the last four quarters.
CervoMed Inc. announced that its drug candidate neflamapimod has been selected for inclusion in the UK's EXPERTS-ALS platform, a government-funded clinical trial designed to rapidly test potential ALS treatments. The trial will initially evaluate neflamapimod in approximately 35 ALS patients over 18-24 weeks, with potential expansion to 80 patients. The selection is based on the drug's targeted mechanism of action and positive clinical data in dementia with Lewy bodies trials.
CervoMed presented Phase 2b trial results showing neflamapimod significantly slows clinical progression in dementia with Lewy bodies, with most prominent improvements in patients without AD co-pathology. The company plans to initiate Phase 3 trials in 2026.
CervoMed will present new data on neflamapimod, a potential treatment for Dementia with Lewy Bodies (DLB), at the 18th Clinical Trials on Alzheimer's Disease Conference, highlighting results from their Phase 2b RewinD-LB trial.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.